Mut. Pharm. Co. v. Bartlett’s Empirical Analysis
570 U.S. 472 · 2013
Citation profile
6 federal appellate · 4 district · 8 state decisions
Relationships
Applies 21 U.S.C. § 301 (Animal Drug Amendments of 1968) · 21 U.S.C. § 348 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 352 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 360K (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 379R (Federal Food, Drug, and Cosmetic Act) · 42 U.S.C. § 300A · 7 U.S.C. § 136A
Relies on Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc. · Motor Vehicle Manufacturers Association of United States Inc v. State Farm Mutual Automobile Insurance Company Consumer Alert · Skidmore v. Swift & Co. · Rice v. Santa Fe Elevator Corp. · Cipollone v. Liggett Group, Inc.
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 53 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“Our pre-emption cases presume that an actor seeking to satisfy both his federal- and state-law obligations is not required to cease acting altogether in order to avoid liability.”
2 later decisions quote this exact passage · from the majority“state-law design-defect claims like New Hampshire's that place a duty on manufacturers to render a drug safer by either altering its composition or altering its labeling are in conflict with federal laws that prohibit manufacturers from unilaterally altering drug composition or labeling.”
1 later decision quote this exact passage · from the majority“the FDCA requires a generic drug to have the same active ingredients, route of administration, dosage form, strength, and labeling as the brand-name drug on which it is based.”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.